Bristol-Myers Squibb’s $14 Billion Potential – Analyst Upgrades Inventory – Bristol-Myers Squibb (NYSE:BMY)

Leerink Companions has upgraded Bristol-Myers Squibb & Co BMY, stating that the corporate enters a catalyst-rich interval in 2025-2027 past Cobenfy (a schizophrenia drug) and milvexian (anticoagulant).

The analyst expects upward strain on Cobenfy (KarXT) and milvexian consensus expectations to drive inventory outperformance from present ranges.

Additionally Learn: Bristol-Myers Squibb Leads Biopharma Restoration With Virtually 25% Progress In Market Cap, However Novo Nordisk And Lilly Endure Market Setbacks

Leerink has upgraded from Market Carry out to Outperform, with a worth goal of $73, up from the earlier $55, and provides that Bristol-Myers inventory trades a considerable low cost to the Diversified Biopharmaceutical median as a result of constrained EPS progress by way of 2029.

However the U.S. pharma large’s publicity to lack of exclusivity (LOE) pressures diminishes in 2030+ relative to friends.

On Monday, AbbVie Inc ABBV inventory fell after two trials investigating emraclidine as a once-daily, oral monotherapy remedy for adults with schizophrenia failed two Part 2 trials.

With AbbVie’s emraclidine Part 2 trial failures, Leerink not anticipates {that a} competing product will launch in 2026, thus boosting long-term Cobenfy projections, together with 2030E gross sales from $4.2 billion to $5.7 billion.

“Cobenfy seems more likely to be a pipeline inside a product, with restricted aggressive threats from stand-alone M4 candidates,” Leerink analyst writes.

Leerink analyst estimates the potential for peak Cobenfy gross sales of over $10 billion if it succeeds in further indications since Eli Lilly And Co’s LLY Zyprexa generated $5 billion in peak income in 2010 at a lot decrease costs.

The analyst has additionally elevated milvexian gross sales projections, with 2030E gross sales from $3.1 billion to $3.9 billion.

“We see the potential for milvexian peak gross sales to be above our 2025E Eliquis gross sales estimate of $14.4 billion if it delivers a superior benefit-risk profile in its atrial fibrillation Part 3 in early 2027.”

Value Motion: BMY inventory is down 0.74% at $59.37 on the final verify on Tuesday.

Learn Subsequent:

Courtesy of Bristol Myers Squibb